NCT01479374View on ClinicalTrials.gov

Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model

PHASE3CompletedINTERVENTIONAL
Enrollment

397

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Allergic Conjunctivitis
Interventions
DRUG

AL-4943A ophthalmic solution

DRUG

AL-4943A vehicle

Inactive ingredients used as placebo

DRUG

Olopatadine hydrochloride ophthalmic solution, 0.2%

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT01479374 - Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model | Biotech Hunter | Biotech Hunter